Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II NGR-hTNF monotherapy in previously treated advanced hepatocellular carcinoma
2006-005696-18Phase 2Active
- Sponsor
- MolMed
- Start
- Feb 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF in hepatocellular carcinoma (HCC), sponsored by MolMed. Primary endpoint: Progression-free survival. Started Feb 2007; status: active.
02
Drugs
NGR-TNF
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-005696-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005696-18.